All News

EULAR 2024 - Day 1 Report https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR OP0041 (2024) COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

#EULAR2024 POS0436 Another benefit of T2T to achieve remission by using less NSAIDs, lower GC, earlier use of SFZ, HCQ and TNF-i = shorter Time to Pregnancy from conception in #RA women (median 84 days) vs without pre-counselling & T2T (196 days) @RheumNow https://t.co/2ZpDLmPVt0

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh

Links:

Janet Pope Janetbirdope ( View Tweet)
ACRmtg.jpg (keep)

EULAR 2024 – Day 3 Report

d Jack Cush, MD

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.

Read Article
Synovitis

Might Synovial Biopsy Predict Rheumatoid Treatment Responses?

d EurekAlert!

Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. 

Read Article
EULAR guidelines for screening for TB in rheumatic disease patients #EULAR2024 https://t.co/jaixl8lGkY

Links:

Jilaine Bolek Berquist BolekBerqui ( View Tweet)
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0

Links:

TheDaoIndex KDAO2011 ( View Tweet)
500+ pts AxSPA No difference in drug discontinuation between IL-17i, TNFi, IL23i over time Adjusted for CRP, co-medication w/ MTX + classic covariates IL-17i and IL-23i had experienced a higher number bDMARD failures #EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Leflunomide for #PMR? ✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica V fast withdrawal of #prednisone #LEF ~4 to 5 months #MTX 30 mos! ⬇️flares w LEF 😮 #EULAR2024 @RheumNow @eular_org @SebaUltraTrail https://t.co/2hk0yMH6gY

Links:

Janet Pope Janetbirdope ( View Tweet)
RA Hands Difficult deformity

EULAR 2024 – Day 2 Report (A Difficult RA Day)

d Jack Cush, MD

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.

Read Article
Stop,pills,water

Can we withdraw treatment in post-menopausal osteoporosis?

d EurekAlert!

Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.

Read Article
scale decision balance question

Dual seropositivity and shared epitopes in RA: friends or foes?

d Aurelie Najm, MD, PhD

Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.

Read Article
What happens when RA patients only on csDMARDs want to stop their meds? in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit! #EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70

Links:

David Liew drdavidliew ( View Tweet)
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs D2T RA pts characterised by ⏰ Earlier disease ⏰ Later initiation of DMARD therapy Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used #EULAR2024 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

OP0140-When should we give #pneumococcal #vaccine to pts starting MTX? Study in RA:PCV13 vaccine given 1 month BEFORE starting MTX leads to higher immunological response at 1m, vs pts vaccinated simultaneously w MTX ⏩Vaccinate patients before starting MTX! @RheumNow #EULAR2024

Mrinalini Dey DrMiniDey ( View Tweet)

Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Can you ⬇️ #Glucocorticoids or #immunesuppressive in #SLE & change am’t of damage From Asia Pacific #lupus collab (Biologics not included) Compared 7.5 mg #prednisone or less Or DMARD 1/2 flared after LLDAS ⬇️dose didn’t prevent damage #EULAR2024 @eular_org @RheumNow https://t.co/QmjEz87Cvw

Links:

Janet Pope Janetbirdope ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.